Related Experiment Videos
Recombinant human growth hormone and Gitelman's syndrome
1Department of Pediatrics, Kyungpook National University School of Medicine, Taegu, South Korea. cwko@bh.kyungpook.ac.kr
Summary
Gitelman's syndrome can cause short stature in children, potentially due to growth hormone (GH) deficiency. Recombinant human GH (rhGH) therapy significantly improved growth rates and corrected hypomagnesemia in a pediatric patient.
Area of Science:
- Pediatric Endocrinology
- Renal Tubular Disorders
- Growth Hormone Therapy
Background:
- Gitelman's syndrome is a genetic disorder affecting renal tubules, leading to electrolyte imbalances and potentially impacting growth in children.
- Short stature is a recognized clinical manifestation in pediatric Gitelman's syndrome, but its underlying cause remains unclear.
- The study investigates the role of growth hormone (GH) deficiency in pediatric short stature associated with Gitelman's syndrome.
Observation:
- A pediatric patient with Gitelman's syndrome presented with height and weight below the third percentile.
- Clinical and radiological assessments suggested a deficiency in growth hormone (GH).
- The patient received recombinant human GH (rhGH) therapy combined with potassium supplementation.
Findings:
- rhGH therapy markedly increased the patient's growth rate from 3.8 cm/yr to 12.0 cm/yr within six months.
- Following cessation of rhGH therapy, the growth rate reverted to the pretreatment level of 3.6 cm/yr.
- Hypomagnesemia, a common feature of Gitelman's syndrome, was effectively corrected during rhGH treatment.
Implications:
- Growth hormone (GH) deficiency may be a contributing factor to short stature in children with Gitelman's syndrome.
- rhGH therapy demonstrates potential as an effective adjunctive treatment for growth-impaired children with Gitelman's syndrome.
- This therapeutic approach may offer benefits for patients resistant to conventional growth-promoting interventions.